Suppr超能文献

九孔插钉试验作为进行性多发性硬化症试验的一项结果指标。

The nine hole peg test as an outcome measure in progressive MS trials.

作者信息

Koch Marcus W, Repovic Pavle, Mostert Jop, Bowen James D, Comtois Jacynthe, Strijbis Eva, Uitdehaag Bernard, Cutter Gary

机构信息

Department of Clinical Neurosciences, University of Calgary, Canada; Department of Community Health Sciences, University of Calgary, Canada.

Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, USA.

出版信息

Mult Scler Relat Disord. 2023 Jan;69:104433. doi: 10.1016/j.msard.2022.104433. Epub 2022 Nov 24.

Abstract

BACKGROUND

The nine-hole peg test (NHPT) is the outcome measure with the least change in secondary and primary progressive MS (SPMS and PPMS) trials. The Standard NHPT is defined as the average of four measurements, two in each hand. Little is known about the performance of alternative NHPT scoring methods as longitudinal outcome measures in progressive MS. Non-ambulatory people with progressive MS are now generally excluded from clinical trials, and there is little information on longitudinal NHPT change in this patient group. In this investigation, we used patient-level data from two large randomized controlled trials in progressive MS to explore alternative NHPT scoring methods and NHPT change in non-ambulatory people with progressive MS.

METHODS

We used patient-level data from the ASCEND (SPMS, n = 889) and PROMISE (PPMS, n = 943) clinical trials to compare significant change on the Standard NHPT with the alternatives dominant hand (DH), non-dominant hand (NDH), and either hand (EH) NHPT in ambulatory and non-ambulatory trial participants.

RESULTS

The Standard NHPT changed slowly and showed few worsening events, as did the DH and NDH alternatives. Using the EH NHPT resulted in a substantial increase of worsening events. Non-ambulatory trial participants with PPMS experienced more NHPT worsening than ambulatory participants, especially when using the EH NHPT.

CONCLUSION

Using the EH NHPT yielded substantially more worsening events in people with progressive MS. Clinical trials in non-ambulatory people may be possible with the NHPT as the primary outcome measure. More research into the precision of these measures in this patient group is necessary.

摘要

背景

九孔插板试验(NHPT)是继发进展型和原发进展型多发性硬化症(SPMS和PPMS)试验中变化最小的疗效指标。标准NHPT定义为四次测量的平均值,两手各测两次。关于替代NHPT评分方法作为进展型多发性硬化症纵向疗效指标的表现,人们了解甚少。进展型多发性硬化症的非步行患者目前通常被排除在临床试验之外,关于该患者群体NHPT纵向变化的信息也很少。在本研究中,我们使用了两项进展型多发性硬化症大型随机对照试验的患者水平数据,以探索替代NHPT评分方法以及非步行进展型多发性硬化症患者的NHPT变化情况。

方法

我们使用了ASCEND(SPMS,n = 889)和PROMISE(PPMS,n = 943)临床试验的患者水平数据,比较了步行和非步行试验参与者中标准NHPT与替代方法优势手(DH)、非优势手(NDH)和任意手(EH)NHPT的显著变化。

结果

标准NHPT变化缓慢,恶化事件较少,DH和NDH替代方法也是如此。使用EH NHPT导致恶化事件大幅增加。PPMS的非步行试验参与者比步行参与者经历了更多的NHPT恶化,尤其是在使用EH NHPT时。

结论

在进展型多发性硬化症患者中,使用EH NHPT产生的恶化事件显著更多。以NHPT作为主要疗效指标,对非步行患者进行临床试验或许可行。有必要对该患者群体中这些指标的精确性进行更多研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验